medigraphic.com
ISSN 3122-3893 (Electronic)

2026, Number S1

<< Back

Rev Mex Traspl 2026; 15 (S1)

Mexican consensus on the diagnosis and management of atypical hemolytic uremic syndrome (aHUS)

Gómez-Navarro B, Morales-Buenrostro LE, Alamilla-Sánchez ME, Álvarez-Rangel LE, Arteaga J, Aréchiga-Andrade M, Bahena-Carrera L, Mejía-Vilet JM, Navarro-Ramírez AC, Rojas-Montaño A, Romo-Vásquez JC, Soto-Abraham MV, Valdez-Ortiz R, Valle-Noriega LA, Reyes-Morales L

Language: Spanish
References: 28
Page: 10-24
PDF size: 931.15 Kb.


ABSTRACT

Introduction: atypical hemolytic uremic syndrome (aHUS) is a rare and potentially life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It is associated with dysregulation of the alternative complement pathway, frequently linked to pathogenic genetic variants. Objective: this expert consensus aims to provide practical, evidencebased clinical recommendations for the diagnosis and management of aHUS, adapted to real-world settings. It also seeks to expedite diagnosis, standardize care criteria, optimize therapeutic decision-making, and reduce clinical variability, particularly in resource-limited settings. Material and methods: a multidisciplinary panel developed 21 clinical recommendations using a modified nominal group technique, supported by a systematic literature review and structured discussion and voting rounds. The recommendations were classified according to the ACC/ AHA system. Results: the consensus addresses aspects such as risk stratification according to complement variants, early initiation of C5 inhibitors, management in the kidney transplantation setting, treatment duration, and criteria for discontinuation or continuation. Conclusion: this consensus provides a structured, evidence-based framework to improve clinical outcomes and promote more equitable care for aHUS in Mexico, with potential applicability to other Latin American settings.


REFERENCES

  1. Campistol JM, Arias M, Ariceta G et al. Actualización ensíndrome hemolítico urémico atípico: diagnóstico y tratamiento.Documento de consenso. Nefrologia. 2015; 35: 421-447. doi:10.1016/j.nefro.2015.07.005.

  2. García RJ, Zamora AR, Perdomo M del RMV, Ochoa AB,Delgado CTC. Síndrome urémico hemolítico atípico. Reporte decaso y revisión de la bibliografía. Acta Pediatr Mex. 2018; 39:250-255. doi: 10.18233/apm39no3pp250-2551609.

  3. Noris M, Caprioli J, Bresin E et al. Relative role of geneticcomplement abnormalities in sporadic and familial aHUS andtheir impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5: 1844-1859. doi: 10.2215/CJN.02210310.

  4. Loirat C, Fakhouri F, Ariceta G et al. An international consensusapproach to the management of atypical hemolytic uremicsyndrome in children. Pediatr Nephrol. 2016; 31: 15-39. doi:10.1007/s00467-015-3076-8.

  5. Noris M, Remuzzi G. Atypical hemolytic–uremic syndrome. N EnglJ Med. 2009; 361: 1676-1687. doi: 10.1056/NEJMra0902814.

  6. Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolyticuraemic syndrome. Lancet. 2017; 390: 681-96. doi: 10.1016/S0140-6736(17)30062-4.

  7. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitoreculizumab in atypical hemolytic–uremic syndrome. N Engl JMed. 2013; 368: 2169-2181. doi: 10.1056/NEJMoa1208981.

  8. Agencia Española de Medicamentos y Productos Sanitarios.Informe de posicionamiento terapéutico de ravulizumab(Ultomiris) en el tratamiento del síndrome hemolítico urémicoatípico (SHUa) [Internet]. Madrid: AEMPS; 2022. Disponibleen: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/2022/IPT_62-2022-Ultomiris-SHUa.pdf

  9. Jones D, Hunter J. Consensus methods for medical and healthservices research. BMJ. 1995; 311: 376-380. doi: 10.1136/bmj.311.7001.376.

  10. Potter M, Gordon S, Hamer P. The nominal group technique: auseful consensus methodology in physiotherapy research. N Z JPhysiother. 2004; 32: 126-130.

  11. McMillan SS, King M, Tully MP. How to use the nominal groupand Delphi techniques. Int J Clin Pharm. 2016; 38: 655-662. doi:10.1007/s11096-016-0257-x.

  12. American Heart Association. Applying class of recommendationand level of evidence to clinical strategies, interventions,treatments, or diagnostic testing in patient care [Internet].Dallas (TX): AHA; 2024. Available in: https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/tables/applyingclass-of-recommendation-and-level-of-evidence

  13. Goodship THJ, Cook HT, Fakhouri F et al. Atypical hemolyticuremic syndrome and C3 glomerulopathy: conclusions froma “Kidney Disease: Improving Global Outcomes” (KDIGO)controversies conference. Kidney Int. 2017; 91: 539-551. doi:10.1016/j.kint.2016.10.005.

  14. Feitz WJC, van de Kar NCAJ, Orth-Holler D, van den HeuvelLPJW, Licht C. The genetics of atypical hemolytic uremicsyndrome. Med Genet. 2018; 30 (4): 400-409. doi: 10.1007/s11825-018-0216-0.

  15. Frémeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics andoutcome of atypical hemolytic uremic syndrome: a nationwideFrench series comparing children and adults. Clin J Am SocNephrol. 2013; 8: 554-562. doi: 10.2215/CJN.04760512.

  16. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJH.Mutations in alternative pathway complement proteins inAmerican patients with atypical hemolytic uremic syndrome.Hum Mutat. 2010; 31: E1445-E1460. doi: 10.1002/humu.21256.

  17. Richards S, Aziz N, Bale S et al. Standards and guidelinesfor the interpretation of sequence variants: a joint consensusrecommendation of the American College of Medical Geneticsand Genomics and the Association for Molecular Pathology.Genet Med. 2015; 17: 405-423. doi: 10.1038/gim.2015.30.

  18. Greenbaum LA, Fila M, Ardissino G et al. Eculizumab is asafe and effective treatment in pediatric patients with atypicalhemolytic uremic syndrome. Kidney Int. 2016; 89: 701-711. doi:10.1016/j.kint.2015.11.026.

  19. Jodele S, Dandoy CE, Aguayo-Hiraldo P, Lane A, Teusink-CrossA, Sabulski A. A prospective multi-institutional study of eculizumabto treat high-risk stem cell transplantation-associated TMA. Blood.

  20. 2024; 143: 1112-1123. doi: 10.1182/blood.2022017654.20. Garnier A, Brochard K, Kwon T et al. Efficacy and safety ofeculizumab in pediatric patients affected by Shiga toxin-relatedhemolytic and uremic syndrome: a randomized, placebocontrolledtrial. J Am Soc Nephrol. 2023; 34: 1561-1573. doi:10.1681/ASN.2023010098.

  21. Zafar A, Lim MY, Abou-Ismail MY. Eculizumab in themanagement of drug-induced thrombotic microangiopathy: ascoping review of the literature. Thromb Res. 2023; 226: 94-102.doi: 10.1016/j.thromres.2023.07.014.

  22. Wright RD, Bannerman F, Beresford MW, Oni L. A systematicreview of the role of eculizumab in systemic lupus erythematosusassociatedthrombotic microangiopathy. BMC Nephrol. 2020;21: 245. doi: 10.1186/s12882-020-01867-0.

  23. Gupta M, Govindappagari S, Burwick RM. Pregnancyassociatedatypical hemolytic uremic syndrome: a systematicreview. Obstet Gynecol. 2020; 135: 46-58. doi: 10.1097/AOG.0000000000003608.

  24. Kidney Disease: Improving Global Outcomes (KDIGO). Clinicalpractice guideline for the evaluation and management of chronickidney disease. Kidney Int Suppl. 2013; 3: 1-150.

  25. Macia M, Alvaro F, Pintos G et al. A retrospective study ofatypical hemolytic uremic syndrome in Spain: identifying riskfactors associated with poor outcomes. Nephrol Dial Transplant.2010; 25: 2959-2965. doi: 10.1093/ndt/gfq099.

  26. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-BacchiV. Use of eculizumab for atypical haemolytic uraemic syndromeand C3 glomerulopathies. Nat Rev Nephrol. 2012; 8: 643-657.doi: 10.1038/nrneph.2012.214.

  27. Licht C, Ardissino G, Ariceta G et al. The global aHUS registry:methodology and initial patient characteristics. BMC Nephrol.2015; 16: 207. doi: 10.1186/s12882-015-0203-4.

  28. Ardissino G, Testa S, Possenti I et al. Discontinuation ofeculizumab maintenance treatment for atypical hemolytic uremicsyndrome: a report of 10 cases. Am J Kidney Dis. 2014; 64: 633-637. doi: 10.1053/j.ajkd.2014.01.434.




2020     |     www.medigraphic.com